Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Amivantamab, a bispecific antibody targeting EGFR/MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zalifrelimab, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tebotelimab, a bispecific antibody targeting PD-1/LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lorigerlimab, a bispecific antibody targeting PD-1/CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Volrustomig, a bispecific antibody targeting PD-1/CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cadonilimab, a bispecific antibody targeting PD-1/CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rilvegostomig, a bispecific antibody targeting PD-1/TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etigilimab, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vibostolimab, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Domvanalimab, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ociperlimab, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tiragolumab, an antibody targeting TIGIT.